Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation.
Steven DeitelzweigAmiee KangJenny JiangChuan GaoXuemei LuoNipun AtrejaStella HanDong ChengSaarusri R LoganathanGregory Yoke Hong LipPublished in: Journal of clinical medicine (2024)
These findings may aid physicians and patients in making informed decisions when considering a switch between apixaban and rivaroxaban.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- venous thromboembolism
- catheter ablation
- left atrial
- left atrial appendage
- end stage renal disease
- direct oral anticoagulants
- heart failure
- ejection fraction
- chronic kidney disease
- primary care
- newly diagnosed
- percutaneous coronary intervention
- peritoneal dialysis
- prognostic factors
- pulmonary embolism
- patient reported
- left ventricular
- coronary artery disease